Friday, April 13, 2018 9:10:05 AM
Nabriva Therapeutics Plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that it will present data at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) taking place in Madrid, Spain from April 21-24, 2018.
These data are part of a growing body of evidence supporting lefamulin's profile as a promising first-in-class pleuromutilin antibiotic treatment for key pathogens, including multidrug resistant strains, known to cause community-acquired bacterial pneumonia (CABP).
“CABP is associated with a substantial economic and humanistic burden with significant morbidity and mortality for patients. With inappropriate use of currently available treatments, antibacterial resistance continues to rise. It is imperative that new classes of antibiotics continue to be developed to provide physicians treatment options for patients with serious infections,” said Jennifer Schranz, M.D., chief medical officer of Nabriva Therapeutics. “Following the positive results from LEAP 1, lefamulin has shown to provide a complete spectrum of activity that covers the most common bacterial causes of CABP, including multidrug resistant strains and atypical pathogens. We look forward to reporting topline efficacy and safety data from our LEAP 2 oral CABP trial this spring.”
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM